CClinicalTrials.gg
Active, not recruitingNCT05348317VetReachUpdated Jul 24, 2026

Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders

An interventional study of VetReach in Substance Use, Substance Use Disorders and Substance Dependence, sponsored by VA Office of Research and Development. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This project will pilot-test and obtain stakeholder input on a telehealth-delivered substance use disorder (SUD) care model (with initial engagement and ongoing MI-CBT treatment) with the goal of increasing treatment utilization and improving outcomes for rural and non-rural Veterans with SUDs.

02

Conditions studied

  • Substance Use
  • Substance Use Disorders
  • Substance Dependence
  • Veterans

Keywords

  • Telehealth
  • Motivational Interviewing
  • Cognitive Behavioral Therapy
  • Rural Health
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's enrollment of 25 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,733 studies on the registry; 396 are open to participants now.

Of its 206 completed or terminated interventional studies of FDA-regulated products, 180 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Veteran patients at the Ann Arbor VA Healthcare System
  • Diagnostic and Statistical Manual of Mental Disorders (DSM-5) SUD diagnosis and/or substance use on average of 2 days a week over the past month
  • Telephone access
  • Able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Receiving SUD psychotherapy
  • Inability to speak or understand English
  • Substantial mental health instability or conditions that preclude informed consent (e.g., acute psychosis, cognitive deficits) or understanding of assessment or program content
  • Prior alcohol withdrawal seizures or delirium tremens
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    MI-CBT Teletx

    The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 \~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).

    Behavioral: VetReach

Interventions

  • BehavioralVetReach

    Telehealth-delivered MI-CBT substance use disorder care model

06

What researchers measure

Primary outcomes

  1. Feasibility of the intervention (engagement)

    Percent (%) of participants engaging in the intervention (at least 3 completed sessions)

    Time frame: 8 weeks

  2. Acceptability of the telehealth intervention

    Study-specific acceptability rating completed by participants (% with a positive rating, higher % is better)

    Time frame: 2 months

Other outcomes

  1. Change in substance consumption

    Substance use/consumption will be assessed using the 30-day Timeline Follow-Back (TLFB). The TLFB will capture information on the frequency and quantity of substance use, with total consumption calculated.

    Time frame: baseline, 8 weeks post-baseline

  2. Change in frequency of substance use as reported on the Timeline Follow-Back (TLFB)

    Based on frequency and quantity, higher scores indicate worse outcome.

    Time frame: baseline, 8 weeks post-baseline

07

Study locations

1 site
  • VA Ann Arbor Healthcare System, Ann Arbor, MI
    Ann Arbor, Michigan 48105-2303, United States
08

References and documents

Study documents

  • Informed consent form · Dec 13, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05348317
Lead sponsor
VA Office of Research and Development
Collaborators
VA Ann Arbor Healthcare System
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
May 19, 2022
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jul 24, 2026

Study contacts

Lewei Lin, MD
principal investigator · VA Ann Arbor Healthcare System, Ann Arbor, MI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion